Last verified: April 2026

UCSD Center for Medicinal Cannabis Research (CMCR)

The Center for Medicinal Cannabis Research at the University of California, San Diego was established in 2000 under the direction of Igor Grant, MD, a neuropsychiatrist and Distinguished Professor at UCSD. The CMCR holds a unique position in U.S. cannabis science: it was created by the California legislature specifically to conduct rigorous clinical research on cannabis therapeutics, funded initially through Proposition 64 (California’s Adult Use of Marijuana Act) tax revenue and supplemented by National Institutes of Health (NIH) grants.

The CMCR has produced some of the most methodologically rigorous clinical trial data in the field. Its research portfolio spans multiple domains:

• Cardiovascular effects — controlled studies of acute and chronic cardiovascular responses to cannabis in human volunteers, including hemodynamic monitoring and cardiac imaging
• Cannabis and driving — simulator studies and on-road assessments quantifying cannabis impairment profiles, the time course of driving performance decrements, and the interaction of cannabis with alcohol
• CBD and alcohol use disorder — randomized trials evaluating cannabidiol as a pharmacotherapy for alcohol dependence, leveraging CBD’s anxiolytic and neuroprotective properties
• Terpene pharmacology — controlled studies of whether specific terpene profiles modulate the therapeutic or adverse effects of THC (testing the entourage effect hypothesis)

The CMCR’s institutional position within a top-tier research university, combined with its legislative mandate and dedicated funding, has allowed it to attract principal investigators who might otherwise avoid cannabis research due to its perceived career risks. Grant’s leadership has been instrumental in demonstrating that rigorous cannabis clinical science is possible within the constraints of federal scheduling.

Johns Hopkins Cannabis Science Lab

The Cannabis Science Lab at Johns Hopkins University School of Medicine is directed by Ryan Vandrey, PhD, a behavioral pharmacologist who has become one of the most prolific cannabis researchers in the United States. The lab operates an unusually large research program: approximately 10–15 concurrent experiments staffed by roughly 40 research personnel, making it one of the largest cannabis-focused academic research groups in the world.

The lab’s landmark initiative is a $10 million NIDA-funded study tracking approximately 10,000 patients across the therapeutic cannabis space — one of the largest observational studies of medical cannabis outcomes ever attempted. The study aims to characterize real-world patterns of cannabis use for medical purposes, treatment outcomes, adverse events, and the relationship between product characteristics and clinical effects in a naturalistic (non-trial) setting.

Vandrey’s lab has been particularly influential in characterizing the pharmacokinetics of different cannabis delivery routes, the reliability (or lack thereof) of commercial cannabis product labeling, edible cannabis dose-response relationships, and secondhand cannabis smoke exposure. The Johns Hopkins brand carries significant weight in legitimizing cannabis research within mainstream academic medicine — a field that has historically viewed cannabis science with institutional skepticism.

The goal is to understand how cannabis is actually being used as medicine in the real world and whether it is helping or harming patients.

Ryan Vandrey, PhD, Johns Hopkins Cannabis Science Lab

University of Sydney — Lambert Initiative for Cannabinoid Therapeutics

The Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney in Australia represents the largest philanthropically funded cannabis research program in the world. Established in 2015 with a $33.7 million (AUD) donation from the Lambert family (the Barry and Joy Lambert Foundation), the Initiative is directed by Iain McGregor, PhD, a psychopharmacologist whose research spans preclinical models, human clinical trials, and regulatory science.

The Lambert Initiative has produced particularly important work in two areas:

• Cannabis and driving — the Initiative has conducted the most sophisticated crossover driving studies to date, using randomized, placebo-controlled designs with on-road driving assessment (the gold standard in impairment research). Their studies have quantified the time course of driving impairment after different cannabis products, demonstrating that impairment from inhaled THC resolves more rapidly than commonly assumed and that CBD does not contribute to driving impairment
• Pediatric epilepsy — building on the Charlotte’s Web story and the Epidiolex approval, the Lambert Initiative has conducted clinical studies of cannabinoid preparations for treatment-resistant epilepsy in children, with a particular focus on optimizing CBD:THC ratios and characterizing the long-term safety profile in pediatric patients

Australia’s regulatory framework (Therapeutic Goods Administration) provides a research-enabling environment that differs from both the U.S. and European models. The Lambert Initiative has leveraged this framework to conduct studies that would face additional regulatory barriers in the United States, generating data that inform global cannabis policy discussions.

Hebrew University — The Mechoulam Legacy

No discussion of cannabis research institutions is complete without Hebrew University of Jerusalem, where Raphael Mechoulam (1930–2023) conducted the foundational work that created the field of cannabinoid science. Mechoulam’s contributions are without parallel: the isolation and synthesis of THC (1964), the isolation and synthesis of CBD (with Yechiel Gaoni, 1963), the discovery of anandamide (with William Devane and Lumír Hanuš, 1992), and foundational work on 2-AG, the endocannabinoid system’s role in inflammation, and cannabinoid chemistry.

Mechoulam’s death in March 2023 marked the end of an era, but the research infrastructure he built at Hebrew University continues to produce world-class cannabinoid science. His former students and collaborators occupy leadership positions in cannabinoid research programs worldwide. The Multidisciplinary Center on Cannabinoid Research at Hebrew University, which Mechoulam helped establish, brings together over 25 researchers across pharmacology, neuroscience, chemistry, and clinical medicine.

Mechoulam was nominated multiple times for the Nobel Prize in Physiology or Medicine. That he never received it is widely regarded as one of the Nobel Committee’s notable omissions — his discovery of THC, the endocannabinoid system, and retrograde lipid signaling transformed our understanding of neuroscience and opened an entirely new field of pharmacology.

Israel’s Research Advantages

Israel produces a disproportionate share of the world’s cannabis research relative to its population of approximately 9.8 million. This outsized output reflects several structural advantages that other countries lack or have only recently begun to develop:

• Regulatory pragmatism — Israel’s Ministry of Health has permitted clinical cannabis research since the 1990s, decades before most other countries. Researchers can obtain approvals to study cannabis without the multi-year, multi-agency process that characterizes the U.S. system
• Military-academic pipeline — Israel’s universal military service creates a research workforce familiar with institutional structures, and several cannabis researchers transitioned from military medical research to academic cannabinoid science
• Medical program scale — Israel has a large medical cannabis program (relative to population) that provides observational data from tens of thousands of patients, enabling the kind of real-world evidence studies that smaller programs cannot support
• Compact geography — a small country with centralized healthcare data allows cohort studies and registry linkages that are logistically difficult in larger, more fragmented healthcare systems
• The Mechoulam effect — Mechoulam’s six decades at Hebrew University created a critical mass of trained cannabinoid scientists, attracting further talent and funding in a self-reinforcing cycle

Israeli research groups have contributed foundational studies on cannabis for PTSD (the Israeli military PTSD program), oncology applications, geriatric palliative care, and epilepsy. The Tikun Olam research program, operating under a Ministry of Health license, has generated clinical data from one of the world’s longest-operating medical cannabis programs.

Other Notable Programs

The cannabis research landscape extends beyond these primary institutions. The University of Colorado Boulder’s Institute of Cognitive Science (Kent Hutchison) operates a mobile pharmacology lab — the "Cannavan" — that tests participants in their homes with their own commercially purchased cannabis, generating ecological validity impossible in conventional laboratory settings. The University of Toronto (Bernard Le Foll) leads Canadian cannabis addiction research. King’s College London (Sagnik Bhattacharyya, Philip McGuire) has produced some of the most important work on cannabis, psychosis, and CBD as an antipsychotic. The University of Bath (Tom Freeman) focuses on cannabis potency trends and their public health implications.

Collectively, these institutions are transforming cannabis science from a niche field conducted under extraordinary constraints into a mainstream discipline with the methodological rigor, institutional support, and funding levels necessary to answer the questions that matter most — who benefits from cannabis, who is harmed, and how the difference can be predicted and managed.